CY1115652T1 - Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες - Google Patents

Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες

Info

Publication number
CY1115652T1
CY1115652T1 CY20141100879T CY141100879T CY1115652T1 CY 1115652 T1 CY1115652 T1 CY 1115652T1 CY 20141100879 T CY20141100879 T CY 20141100879T CY 141100879 T CY141100879 T CY 141100879T CY 1115652 T1 CY1115652 T1 CY 1115652T1
Authority
CY
Cyprus
Prior art keywords
pellet
dosage form
different natural
mixing ingredients
natural forms
Prior art date
Application number
CY20141100879T
Other languages
Greek (el)
English (en)
Inventor
Sandra Blundell
Panagiotis Keramidas
Brett Antony Mooney
Todd James Rutherford
Original Assignee
Alphapharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007900682A external-priority patent/AU2007900682A0/en
Application filed by Alphapharm Pty Ltd filed Critical Alphapharm Pty Ltd
Publication of CY1115652T1 publication Critical patent/CY1115652T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20141100879T 2007-02-09 2014-10-27 Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες CY1115652T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007900682A AU2007900682A0 (en) 2007-02-09 Novel Formulation
EP20080706056 EP2120878B1 (en) 2007-02-09 2008-02-11 A dosage form containing two active pharmaceutical ingredients in different physical forms

Publications (1)

Publication Number Publication Date
CY1115652T1 true CY1115652T1 (el) 2017-01-25

Family

ID=39681201

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100879T CY1115652T1 (el) 2007-02-09 2014-10-27 Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες

Country Status (15)

Country Link
US (1) US9095519B2 (cg-RX-API-DMAC7.html)
EP (1) EP2120878B1 (cg-RX-API-DMAC7.html)
JP (1) JP5467870B2 (cg-RX-API-DMAC7.html)
CN (1) CN101674811B (cg-RX-API-DMAC7.html)
AU (1) AU2008213744B2 (cg-RX-API-DMAC7.html)
CA (1) CA2677623C (cg-RX-API-DMAC7.html)
CY (1) CY1115652T1 (cg-RX-API-DMAC7.html)
DK (1) DK2120878T3 (cg-RX-API-DMAC7.html)
ES (1) ES2522297T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20141008T1 (cg-RX-API-DMAC7.html)
NZ (1) NZ599031A (cg-RX-API-DMAC7.html)
PL (1) PL2120878T3 (cg-RX-API-DMAC7.html)
PT (1) PT2120878E (cg-RX-API-DMAC7.html)
SI (1) SI2120878T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008095263A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100189797A1 (en) * 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2184055A1 (en) * 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
CN101780078B (zh) * 2010-02-10 2012-02-29 威特(湖南)药业有限公司 替米沙坦和氨氯地平复方制剂及其制备方法
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
ES2581158T3 (es) * 2010-05-06 2016-09-01 Cal International Limited Una composición farmacéutica que comprende aspirina y bisoprolol
CN102247366B (zh) * 2010-05-18 2015-04-15 广州白云山制药股份有限公司广州白云山制药总厂 包括依那普利和非洛地平的药物组合物缓释制剂
CN102028670A (zh) * 2010-09-06 2011-04-27 邓俐丽 一种包含替米沙坦和钙离子通道拮抗剂的复方胶囊剂
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
BR112014008744A2 (pt) 2011-10-21 2017-04-18 Takeda Pharmaceuticals Co preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
CN104010632B (zh) 2011-12-21 2016-08-24 瑞士诺华动物保健有限公司 双层片剂形式的贝那普利和匹莫苯的固定剂量组合
CN103169704A (zh) * 2011-12-26 2013-06-26 上海复星医药产业发展有限公司 烟酸和辛伐他汀复方缓释胶囊制剂及其制备方法
BR112014020184B1 (pt) 2012-02-17 2021-11-30 Egis Gyógyszergyár Zrt Preparação farmacêutica que contém anlodipina e ra-mipril
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CN102670630B (zh) * 2012-05-23 2013-11-27 重庆康刻尔制药有限公司 一种缬沙坦与氢氯噻嗪药物组合物胶囊剂及其制备方法
EP2890366A1 (en) * 2012-08-28 2015-07-08 DSM Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at least one of them is in the form of mini-tablets
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
HUP1300496A2 (hu) 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
CN103462903B (zh) * 2013-08-26 2016-06-22 中国人民解放军第150中心医院 一种盐酸吡格列酮缓释微丸制剂的制备工艺
US9566248B2 (en) * 2013-09-13 2017-02-14 R.P. Scherer Technologies, Llc Encased-pellet tablets
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
CN104382896A (zh) * 2014-11-04 2015-03-04 万全万特制药江苏有限公司 含有依折麦布和辛伐他汀的药物组合物
CN107920987A (zh) * 2015-05-26 2018-04-17 艾萨·欧蒂迪 控制延缓释放普瑞巴林
EP3328494A4 (en) 2015-08-01 2019-04-03 Stephen J. Petti COMPOSITIONS AND METHODS FOR COMBINING PHARMACOLOGICAL TREATMENTS TO INDUCTION EXTENDED, Mild Acceptance of BODY CORE TEMPERATURE
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
JP6831645B2 (ja) * 2016-06-14 2021-02-17 エルメッド株式会社 ガランタミン含有医薬組成物、医薬組成物におけるガランタミンの安定化方法、及びガランタミンの安定化剤
CR20190577A (es) 2017-07-17 2020-01-29 Lilly Co Eli Composiciones farmacéuticas
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
CN111388480B (zh) * 2020-03-26 2022-05-31 江苏长泰药业有限公司 一种奥氮平盐酸氟西汀复方制剂及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
WO1998006385A1 (de) 1996-08-15 1998-02-19 Losan Pharma Gmbh Gut schluckbare orale arzneiform
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
ID26861A (id) * 1998-05-22 2001-02-15 Lilly Co Eli Terapi gabungan untuk pengobatan depresi refaktori
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
SI1140105T1 (en) * 1998-12-24 2004-04-30 Janssen Pharmaceutica N.V. Controlled release galantamine composition
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
PL362687A1 (en) * 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
EP1248599B1 (de) * 2001-01-31 2007-12-05 Evonik Röhm GmbH Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CA2477260C (en) * 2002-03-12 2009-05-19 Microdose Technologies, Inc. Site specific delivery of co-administered drugs via inhalation
US6690577B2 (en) * 2002-07-02 2004-02-10 Hewlett-Packard Development Company, L.P. Air guide
MXPA05004410A (es) 2002-10-25 2005-11-23 Labopharm Inc Composiciones de liberacion controlada.
MXPA05006954A (es) 2002-12-26 2005-09-22 Pozen Inc Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
WO2004062552A2 (en) * 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005011642A1 (en) * 2003-08-05 2005-02-10 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
JP4897483B2 (ja) * 2003-09-03 2012-03-14 ファルマトン ソシエテ アノニム 異なる放出プロフィールを有する活性物質ぺレット含有カプセル
ES2326251B1 (es) * 2005-06-12 2010-07-08 Elan Pharma International Limited Composiciones de ticlopidina de liberacion modificada.

Also Published As

Publication number Publication date
CN101674811B (zh) 2015-08-19
EP2120878A1 (en) 2009-11-25
NZ599031A (en) 2013-11-29
AU2008213744A1 (en) 2008-08-14
CA2677623C (en) 2015-04-07
DK2120878T3 (da) 2014-11-03
HRP20141008T1 (hr) 2015-01-02
PT2120878E (pt) 2014-11-05
US9095519B2 (en) 2015-08-04
CA2677623A1 (en) 2008-08-14
CN101674811A (zh) 2010-03-17
PL2120878T3 (pl) 2015-01-30
JP2010518028A (ja) 2010-05-27
JP5467870B2 (ja) 2014-04-09
SI2120878T1 (sl) 2014-12-31
EP2120878A4 (en) 2013-05-08
WO2008095263A1 (en) 2008-08-14
ES2522297T3 (es) 2014-11-14
EP2120878B1 (en) 2014-07-30
AU2008213744B2 (en) 2013-12-05
US20100092549A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
CY1119817T1 (el) Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
UA116334C2 (uk) Тверді форми дозування бендамустину
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
PH12015500823A1 (en) Modified release formulations for oprozomib
AR105184A1 (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
UA115257C2 (uk) Фармацевтична композиція у формі твердої суміші, що містить кандесартану цилексетил та амлодипін
SI2906233T1 (en) Pharmaceutical forms for the treatment and prevention of obesity
CR20120432A (es) Formulaciones farmacéuticas sólidas de ramipril y besilato de amlodipino y su preparación
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
CY1120749T1 (el) Φαρμακευτικες δοσολογικες μορφες
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
MX2018015759A (es) Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
WO2019203759A3 (en) Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation.
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
HRP20160811T1 (hr) Upotreba odiparcila u liječenju mukopolisaharidoze
WO2016028903A8 (en) Oral transmucosal pharmaceutical compositions including testosterone and a c-serm